An interventional study of 0.01% atropine eye drops and 0.05% atropine eye drops in Myopia and Pre-myopia, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Recruiting at 1 site in China. Open to participants aged 3 Years to 6 Years. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.
Among the 54 studies testing atropine in Myopia, this one is the 6th largest by planned enrollment, is one of 5 that started in 2025, is one of 13 with no phase, reaches primary completion later than 12 of the 23 other live ones, and was the 46th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:
Jaeb Center for Health Research · Sites in United States
Ages 5–11
Ohio State University · Sites in United States
Ages 6–11 · Healthy volunteers
IDB VisionCare SDN BHD · Sites in Malaysia
Ages 5–10
Ocus Innovation Ireland Limited · Sites in Albania, Italy, Poland and 2 more countries
Ages 3–17
Oupushifang Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 6–12
By country, each count listing its studies:
Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 3 Years to 6 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 16 · Phase 4 8
First in 2005; this study’s year is marked. 5 started in 2025.
This study's planned enrollment of 508 is above the median of 79 across 929 interventional studies indexed under Myopia.
Median enrollment 144 across the 54 interventional studies. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 54 have an industry lead sponsor. The 10 most frequent:
Shanghai Eye Disease Prevention and Treatment Center is the lead sponsor of 67 studies on the registry; 31 are open to participants now.
42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center: 21 open now, 22 under way, none of them phase 3. Of 8 finished, 0 (0%) have results posted.
Among the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, this one is the 3rd largest by planned enrollment of the 36 interventional ones that give a count, is one of 7 that started in 2025, is one of 32 with no phase, reaches primary completion later than 9 of the 21 other live ones, and was the 30th registered.
Shanghai Eye Disease Prevention and Treatment Center’s Myopia studies by the year they started, since 2016.
8 of the studies testing atropine in Myopia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT07329777Phase 3IDB VisionCare SDN BHDAtropine in the Treatment of Myopia Study in Malaysia | 2027-09 |
| NCT07164092Phase 3Mansoura UniversityEfficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center | 2027-09 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
| NCT05379855Eye & ENT Hospital of Fudan UniversityA-eyedrops on Ocular Alignment and Binocular Vision | 2027-02-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 54 studies testing atropine in Myopia, from their registry updates:
Among Shanghai Eye Disease Prevention and Treatment Center’s 42 in Myopia:
This tab as a report to print or save as PDF → With an account.
The prevalence of myopia among children has been increasing year by year, which has become a globle public health issue. Studies have shown that defocusing lenses and atroping eyedrops can control the progression of myopia, but there is little evidence of its efficacy in myopia intervention of young pre-schoolers who will face a greater risk of progression to high myopia later in life. Therefore, this study aims to evaluate the effectiveness and safety of spectacle lenses with highly aspherical lenslets (Essilor's Stellest) , as well as 0.01% and 0.05% low concentration atropine eyedrops in myopia intervention among young children aged 3-6.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No intervention for myopia control
Wearing spectacle lenses with highly aspherical lenslets for myopia control
Device: Spectacle lenses with highly aspherical lenslets
Nightly use of 0.01% atropine eyedrops for myopia control
Drug: 0.01% atropine eye drops
Nightly use of 0.05% atropine eyedrops for myopia control
Drug: 0.05% atropine eye drops
Participants will use 0.01% atropine eyedrops nightly for myopia control.
Participants will use 0.05% atropine eyedrops nightly for myopia control.
These are a special type of eyeglass lenses designed primarily to slow down the progression of myopia (nearsightedness) in children. The center of the lens provides a clear correction for distance vision, just like regular glasses. The surrounding area contains hundreds of tiny, invisible, and highly aspherical (complex curved) microlenses. These microlenses create a special optical effect. While the child looks straight ahead clearly, peripheral light rays are focused in front of the retina. This is called "myopic defocus." Research suggests that this myopic defocus signal helps to control the excessive elongation of the eyeball, which is the main cause of myopia getting worse.
Changes in cycloplegic spherical equivalence
Measured by an auto-refractometer
Time frame: 2 year
Changes in axial length
Measured by an IOL-Master
Time frame: 2 years
Proportion of subjects with non-rapid myopia progression
Rapid myopia progression is defined as: spherical equivalence increase (become less positive or more negative refractive error) of any eye ≥ 0.5 D in half a year.
Time frame: 2 years
The duration of non-rapid myopia progression
Rapid myopia progression is defined as: spherical equivalence increase (become less positive or more negative refractive error) of any eye ≥ 0.5 D in half a year.
Time frame: 2 years
Changes in choroid/retina thickness
Measured by SS-OCT
Time frame: 2 years
Changes in BCVA
Best corrected visual acuity
Time frame: 2 years
Changes in IOP
Intraocular pressure
Time frame: 2 years
Changes in AMP
Amplitude of Accommodation
Time frame: 2 years
Changes in Stereopsis
Using Titmus Fly Test
Time frame: 2 years
Changes in TBUT
Tear Film Break-Up Time
Time frame: 2 years
Changes in anterior segment parameters
Measured by Pentacam
Time frame: 2 years
Changes in Hemodynamic Parameters of the Ocular Fundus
Measured by SS-OCTA
Time frame: 2 years
Compliance indicators
Daily wearing duration, wearing habits and patterns, frequency of eye drops use.
Time frame: 2 years
Side Effects and Adverse Events
Incidence of glare, diplopia, blurred vision, photophobia, etc.
Time frame: 2 years
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 24 months is close to that.
Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atropine
Shanghai Eye Disease Prevention and Treatment Center